Skip to main content

PIEZO1 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-10504

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-10504

Key Product Details

Validated by

Knockout/Knockdown

Species Reactivity

Validated:

Human, Mouse, Rat, Porcine, Rabbit

Cited:

Mouse, Rat

Applications

Validated:

ELISA, Immunohistochemistry, Knockdown Validated, Western Blot

Cited:

Immunocytochemistry/ Immunofluorescence, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

LYOPH mg/ml

Product Specifications

Immunogen

Synthetic peptide derived from C-terminal domain of human Protein FAM38A.

Specificity

Reacts with human 287 kDa Protein FAM38A. Cross-reacts with mouse, rat, rabbit and other species due to sequence homology. Piezo-type mechanosensitive ion channel component 1.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for PIEZO1 Antibody

Knockdown Validated: PIEZO1 Antibody [NBP2-10504]

Knockdown Validated: PIEZO1 Antibody [NBP2-10504]

Knockdown Validated: PIEZO1 Antibody [NBP2-10504] - PC2, TRPV4, and PIEZO1 localize to MLO-Y4 primary cilia and plasma membrane. Chemiluminescence-detected Western blot of PC2, TRPV4, PIEZO1 antibody, and actin protein in MLO-Y4s treated with scrambled control siRNA and Pkd2, Trpv4, or Piezo1 siRNA. Image collected and cropped by CiteAb from the following publication (https://ciliajournal.biomedcentral.com/articles/10.1186/s13630-015-0016-y) licensed under a CC-BY license.
PIEZO1 Antibody

Western Blot: PIEZO1 Antibody [NBP2-10504] -

Western Blot: PIEZO1 Antibody [NBP2-10504] - PC2, TRPV4, & PIEZO1 localize to MLO-Y4 primary cilia & plasma membrane. (A–C) Localization of PC2, TRPV4, & PIEZO1 on MLO-Y4 primary cilia & plasma membrane. Acetylated alpha-tubulin is in enriched primary cilia. Scale bars, 10 μm. (D) Chemiluminescence-detected Western blot of PC2, TRPV4, PIEZO1, & actin protein in MLO-Y4s treated with scrambled control siRNA & Pkd2, Trpv4, or Piezo1 siRNA. (E) Quantified knockdown of Pkd2 (n = 4), Trpv4 (n = 10), & Piezo1 (n = 4) mRNA expression in MLO-Y4 cells treated with siRNA relative to controls (n = 10). Error bars show ±SEM. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26029358), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for PIEZO1 Antibody

Application
Recommended Usage

Immunohistochemistry

1:50-1:500

Western Blot

1:500-1:2000
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Lyophilized powder, reconstitute to 1 mg/ml in distilled water.

Formulation

0.1M Tris , 0.1M Glycine and 2% Sucrose

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: PIEZO1

PIEZO1 (piezo-type mechanosensitive ion channel component 1) plays a crucial role in epithelial cell adhesion. PIEZO1 belongs to the PIEZO family of transmembrane proteins. Mutations in Piezo1 have been tied to Xerocytosis. PIEZO1 has been studied in relation to neuronitis, Alzheimer's disease and Parkinson's disease.

Long Name

Piezo-type mechanosensitive ion channel component 1

Alternate Names

FAM38A, KIAA0233, Mib, Protein FAM38A

Entrez Gene IDs

9780 (Human); 234839 (Mouse); 361430 (Rat)

Gene Symbol

PIEZO1

UniProt

Additional PIEZO1 Products

Product Documents for PIEZO1 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for PIEZO1 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...